Compare CPF & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPF | ESPR |
|---|---|---|
| Founded | 1954 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 849.9M | 898.5M |
| IPO Year | N/A | 2013 |
| Metric | CPF | ESPR |
|---|---|---|
| Price | $31.84 | $3.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $34.50 | $6.67 |
| AVG Volume (30 Days) | 160.7K | ★ 5.6M |
| Earning Date | 01-28-2026 | 03-03-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ 15.70 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | $260,672,000.00 | ★ $303,802,000.00 |
| Revenue This Year | $1.70 | $26.11 |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $13.11 | ★ N/A |
| Revenue Growth | ★ 6.55 | 2.83 |
| 52 Week Low | $23.16 | $0.69 |
| 52 Week High | $33.35 | $4.18 |
| Indicator | CPF | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 32.93 |
| Support Level | $30.42 | $3.00 |
| Resistance Level | $32.53 | $4.18 |
| Average True Range (ATR) | 0.75 | 0.23 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 58.19 | 4.26 |
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.